Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
With five novel therapies shown to improve survival in metastatic castration-resistant prostate cancer (CRPC) in the last 3 years, patients are now living longer and experiencing better quality of life. Since docetaxel became standard of care for men with symptomatic metastatic CRPC, three artificial treatment "spaces" have emerged for prostate cancer drug development: pre-docetaxel, docetaxel combinations, and following docetaxel. Multiple therapies are currently under development in both early and late stage CRPC. Additionally, the novel agents abiraterone, radium-223, cabazitaxel, and enzalutamide have all been approved in the post-docetaxel setting. Strategies for patient selection and treatment sequencing are therefore urgently required. In this comprehensive review, we will summarize the preclinical and clinical data available with regards to sequencing of the novel treatments for CRPC.
Department of Internal Medicine, Division of Hematology/Oncology, American University of Beirut Medical Center, PO box 11-0236, Riad El Solh, Beirut, 1107 2020, Lebanon, Dm25@aub.edu.lb.
Deborah
D
Mukherji
Aurelius
A
Omlin
Carmel
C
Pezaro
Ali
A
Shamseddine
Johann
J
de Bono
D000818:Animals; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D055808:Drug Discovery; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology* / Q000628:therapy; D016896:Treatment Outcome